[1]
Mortazavi A, Mohammad S, Mortazavi J, Sihver L. Selective pressure-free treatments for COVID-19. Radiat 2021; 1(1): 18-32.
[2]
Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med 2020; 18(1): 179.
[3]
Finkel Y, Mizrahi O, Nachshon A, et al. The coding capacity of SARS-CoV-2. Nature 2021; 589(7840): 125-30.
[5]
Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog 2020; 16(8): e1008762.
[6]
Cosar B, Karagulleoglu ZY, Unal S, et al. The most recent SARS-CoV-2 mutations and their subsequent viral variants. Cytokine Growth Factor Rev 2021.
[7]
Li X, Wang W, Zhao X, et al. Transmission dynamics and evolutionary history of 2019‐nCoV. J Med Virol 2020; 92(5): 501.
[10]
Kupferschmidt K. The pandemic virus is slowly mutating. But does it matter? Science 2020; 369(6501): 238-9.
[11]
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 2020; 5(1): 1-10.
[12]
Oberemok VV, Laikova KV, Yurchenko KA. SARS-CoV-2 will continue to circulate in the human population: An opinion from the point of view of the virus-host relationship. Inflamm Res 2020; 69(7): 635-40.
[14]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[16]
Consortium WST. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med 2020; 384(4): 497-511.
[17]
Poudel S, Ishak A, Perez-Fernandez J, et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – What is known so far? Travel Med Infect Dis 2022; 45: 102234.